NEWS

The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...

Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...

The passage of last year’s Inflation Reduction Act (IRA) made major structural changes to the way Medicare covers and pays for...

Employers and unions are getting fed up with the firms they have used for years to help control their spending on prescription...

Clinical development programs for new drugs include an array of research conducted both before and after a drug’s initial approval by the...

Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug...

Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve...

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the...

The U.S. Department of Health and Human Services (HHS) on Tuesday announced the first 10 drugs covered under Medicare Part D to be...

WASHINGTON — Medicare can now negotiate lower prices for 10 common high-price drugs, cutting out-of-pocket costs for an estimated 9...

Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world...

By Reuters FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration...

It’s been almost one year since Congress and the Biden administration passed the Inflation Reduction Act (IRA), and so far leaders in the...

The biotech industry split off into two conference camps in early June: Oncology researchers headed to Chicago for the American Society...

A panel hosted last week by JP Morgan and the industry group PhRMA further hinted at possible sweeping changes to the U.S. drug...

The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says. The Inflation...

As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you...

CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster...

The IRA is leading pharmas to forego fast-to-patient development strategies in favor of getting onto the market first with the largest...

Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will...